Abstract: A device for measuring an intracellular ion concentration in a living cell into which a fluorescent probe dye has been introduced. A concentration of an ion in the cell is measured based on intensities of fluorescence generated by irradiating the cell with excitation beams, and comparing the intensities of fluorescence emitted by the cell with fluorescence intensities generated from each of 3 reference solutions irradiated with excitation beams. The device is composed of a container means for holding an object to be measured, an excitation beam irradiating means, a fluorescence intensity detecting means, a first processing means for receiving output signals of the fluorescence intensity detecting means and a second processing means for solving simultaneous equations to determine a concentration of the ion to be measured within the cell.

Abstract: Compounds of formula I, and their pharmaceutically acceptable salts, ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl or alkenyl; or NR.sup.1 R.sup.2 is a heterocyclic group; A is trimethylene optionally substituted by alkyl and the phenyl ring is optionally substituted by substituents such as halogeno, alkenyl, amino, cyano, ureido, alkyl, carbamoylalkyl, alkanoylamino, alkoxycarbonyl, N-alkyl-alkanoylamino, alkanoyl and amines thereof; are inhibitors of squalene synthese and hence useful in treating diseases in which a lowering of cholesterol is desirable. As well as the use of these compounds in medicine, novel compounds, processes for their preparation and pharmaceutical compositions are also referred to.

Abstract: A process for preparing an antifungal azole compound of formula (I) by reacting an epoxide with hydrazine to from a hydrazino compound which is subsequently reacted with an iminoether. The amidrazone product is subsequently reacted with an orthoformate to provide the antifungal azole. The azole, known as ZD0870, shows good activity against human fungal infections including Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus.

Abstract: A bipolar electrocautery valvulotome in the form of an elongated catheter having a longitudinal axis, a proximal end for being held and manipulated by a user, and a distal end. A first electrode is provided adjacent the distal end of a main body of the catheter and has an exposed surface facing distally of the catheter. The first electrode is electrically coupled to device for generating a current. A second electrode is disposed distally of the first electrode and is also electrically coupled to the current generating device. The second electrode has an exposed surface in a plane substantially perpendicular to the longitudinal axis of the catheter. At least one of the first and second electrodes is movable relative to the other so as to selectively capture a venous valve structure to be cauterized therebetween.

Abstract: A steering wheel assembly having a slidably mounted locking system of the boss plate to connect the steering wheel onto a steering shaft. The lock system comprises a fixing device slidably mounted on an upper surface of a boss plate. The fixing device includes an inwardly directed, tapered tongue or flange that when slid will engage and interact with the steering shaft. When the boss plate is mounted on the steering shaft provided about the circumference of a nut mounted on the steering shaft, the fixing device can then be moved with a screw bolt thereby interlocking the locking tongue or flange in the groove thereby locking the steering wheel on the steering shaft.

Abstract: The invention relates to tricyclic compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, hydroxy-(1-4C)alkyl or fluoro-(1-4C)alkyl; R.sup.2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy-(2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Ar is optionally-substituted phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl; and R.sup.3 includes a group of the formula --NHCH(CO.sub.2 H)--A.sup.1 --Y.sup.1 wherein A.sup.1 is (1-6C)alkylene and Y.sup.1 is carboxy, tetrazol-5-yl, N-?(1-4C)alkylsulphonyl!carbamoyl, N(phenylsulphonyl)carbamoyl, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or pharmaceutically-acceptable salts or esters thereof; to processes for their manufacture; to pharmaceutical compositions containing them; and to their use as anti-cancer agents.

Abstract: A substrate, which has a high thermal conductivity material layer having a thermal conductivity of at least 10 W/cm.multidot.K and which has a cooling medium flow path on or in the high thermal conductivity material layer, has a high heat-dissipating property.

Abstract: A compound of the general formula(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A Iwherein: n is 0 or 1;M.sup.1 is an amino group;Q is an aromatic heterocyclic group containing a basic nitrogen atom;M.sup.2 is an imino group;L is a template group; andA is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group;and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

Abstract: Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as anaesthetics.A method for their preparation is described, as their use in producing anaesthesia including induction and maintenance of general anaesthesia and sedation.

Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts in which R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 --CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.ident.C--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --N.dbd.CH--, --CH.dbd.N--, --CH.sub.2 S-- and --SCH.sub.

Abstract: Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as anaesthetics.A method for their preparation is described, as their use in producing anaesthesia including induction and maintenance of general anaesthesia and sedation.

Abstract: Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.

Abstract: Terephthalic acid is produced by oxidation of para xylene, purified in an aqueous phase and recovered by precipitating a purified product from the aqueous phase, the aqueous phase mother liquor is then cooled or evaporated to produce a further less pure precipitate and a second mother liquor and the less pure precipitate is returned to the reaction medium and/or the water of the second mother liquor is used to dissolve the crude solid and/or the second mother liquor is treated to recover water which is used to wash the precipitate recovered from the aqueous solution. The process produces better yields of terephthalic acid, reduces the use of water and reduces problems in the disposal of polluted waste water.